EP
KNSA icon

Essential Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Essential Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.7K Sell
684
-1,242
-64% -$64.4K 0.02% 647
2026
Q1 		$92.7K Hold
1,926
– – 0.03% 437
2025
Q4 		$79.4K Buy
1,926
+3
+0.2% +$120 0.02% 502
2025
Q3 		$74.7K Buy
1,923
+1
+0.1% +$32 0.02% 493
2025
Q2 		$53.2K Buy
+1,922
New +$48.9K 0.02% 461

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Essential Partners's KNSA Position: Q2 2026 in Review

Essential Partners reduced its Kiniksa Pharmaceuticals (KNSA) stake by 64% in Q2 2026, selling an estimated $64.4K and leaving 684 shares worth $43.7K. The position accounts for 0.02% of the portfolio, ranked #647.

Essential Partners first reported a position in KNSA in Q2 2025 and has held it in 5 quarters since. The position peaked at $92.7K in Q1 2026. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Essential Partners held 684 shares of Kiniksa Pharmaceuticals worth $43.7K as of Q2 2026.
  • Essential Partners sold 1,242 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $64.4K.
  • Kiniksa Pharmaceuticals made up 0.02% of Essential Partners's portfolio in Q2 2026, its #647 holding.
  • Essential Partners first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Kiniksa Pharmaceuticals position peaked at $92.7K in Q1 2026.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.